What are the adult indications, dosing regimen, therapeutic monitoring, and safety considerations for cyclosporine?

Cyclosporine: Adult Indications, Dosing, Monitoring, and Safety

FDA-Approved Indications

Cyclosporine is FDA-approved for psoriasis (≥16 years) and organ transplantation, with limited-term use up to 1 year recommended for psoriasis. 1, 2

• Off-label use for atopic dermatitis is conditionally recommended for adults with refractory moderate to severe disease, though not FDA-approved for this indication in the United States 2
• Other dermatologic conditions with good evidence include Behçet disease, chronic spontaneous urticaria, graft-versus-host disease, palmoplantar pustulosis, and pyoderma gangrenosum 2

---

Dosing Regimen

Psoriasis

Start at 2.5 mg/kg/day divided twice daily, with dose escalation every 2 weeks by 0.5 mg/kg/day up to a maximum of 4 mg/kg/day based on response. 1, 2

• Patients should remain at the initial 2.5 mg/kg/day dose for at least 4 weeks before increasing 1
• For severe disease requiring rapid control, initiate at the higher end (5 mg/kg/day) 2
• Once adequate control is achieved, taper gradually in steps of 0.5-1 mg/kg to the lowest effective dose 2
• Limit continuous treatment to 6 months when possible; intermittent short courses are safer than continuous therapy 2
• Clinical improvement typically occurs within 2 weeks, with satisfactory control achieved in 12-16 weeks 1

Atopic Dermatitis

The recommended starting dose is 3-5 mg/kg/day divided twice daily for refractory moderate to severe disease. 2

• Evidence from a body-weight-independent study suggests 150 mg daily may be effective with better renal tolerability than 300 mg daily, though 300 mg shows faster response 3
• Duration should be limited to short-term use, ideally up to 6 months, following the FDA-approved psoriasis precedent 2

Critical Administration Details

• Take on an empty stomach or before meals 2
• Avoid grapefruit and grapefruit juice completely—they inhibit CYP3A4 and increase cyclosporine levels 2
• Dilute oral solution preferably with orange or apple juice at room temperature; milk combinations are unpalatable 1
• Ensure patients receive the same formulation consistently—modified and non-modified forms have different bioavailability 1

---

Therapeutic Monitoring

Baseline Assessment (Before Starting)

Obtain at least 2-3 serum creatinine measurements to establish a reliable baseline mean, as spontaneous day-to-day fluctuation is considerable. 2

Additional baseline requirements 2:

• Blood pressure (two measurements)
• Complete blood count
• Liver function tests
• Fasting lipids, electrolytes, uric acid, urinalysis
• Hepatitis B and C serology
• HIV serology in high-risk groups
• Varicella zoster serology (if no history of chickenpox or vaccination)
• Interferon-gamma release assay and chest X-ray when tuberculosis risk factors exist

Ongoing Monitoring Schedule

During the first 2 months: measure serum creatinine and blood pressure every 2 weeks. 2

After 2 months: monthly monitoring of creatinine and blood pressure. 2

After 4 months of stable parameters: monitoring every 2-3 months is adequate for long-term treatment. 2

• CBC, uric acid, potassium, lipids, and magnesium should be monitored every 2 weeks for the first 3 months, then monthly 1

Therapeutic Drug Monitoring

Blood concentration monitoring is routinely recommended in transplant patients but only periodically in dermatologic conditions. 1

• Trough levels (C0) of 150-250 μg/L and peak levels at 2 hours (C2) of 500-1000 μg/L balance efficacy with safety 4
• C2 monitoring provides more precise dosing optimization than trough monitoring alone 5
• For patients under 40 years: target dose 4.5-5.5 mg/kg/day; over 40 years: 3.5-4.5 mg/kg/day 4

---

Dose Adjustment Criteria

For Elevated Creatinine

If serum creatinine rises ≥25% above baseline: repeat within 2 weeks; if sustained, reduce dose by 25-50%. 1

If creatinine rises ≥50% above baseline: immediately reduce dose by 25-50%. 1

Discontinue if creatinine elevation is not reversible (within 25% of baseline) after two dose modifications. 1

For Hypertension

Reduce dose by 25-50% for sustained hypertension in previously normotensive patients. 1

Discontinue if hypertension persists despite multiple dose reductions or if antihypertensive management changes are ineffective/intolerable. 1

For Other Adverse Events

Reduce dose by 25-50% for any clinically significant laboratory abnormality or adverse event. 1

---

Safety Considerations and Contraindications

Absolute Contraindications

Do not use in patients with uncontrolled hypertension, abnormal renal function, or severe hepatic dysfunction. 2

• Active serious infections should be treated before initiating cyclosporine 2
• Pregnancy and breastfeeding are contraindications 2
• Unwillingness to undergo monitoring is a contraindication 2

Major Adverse Effects

Nephrotoxicity is dose-related and the most significant concern—monitor creatinine closely and adjust doses promptly. 2, 1

Hypertension occurs commonly; measure blood pressure at every visit. 2, 1

Increased risk of non-melanoma skin cancer, particularly in patients previously exposed to high-dose UV therapy (PUVA, UVB). 2

• Common adverse effects include hypertrichosis (72%), gingival hyperplasia (61%), hyperuricemia (63%), and hyperlipidemia (47%) 4
• Hyperlipidemia should be managed initially with dietary restriction; if pharmacotherapy needed, use statins/fibrates cautiously due to interaction risk 2
• Avoid concurrent nephrotoxic drugs (NSAIDs, aminoglycosides, amphotericin B) as they potentiate renal dysfunction 2, 1

Critical Drug Interactions

Numerous drugs alter cyclosporine levels via CYP3A4 inhibition or induction—check interactions whenever adding medications. 2, 1

Drugs that increase cyclosporine levels (requiring dose reduction) 2, 1:

• Calcium channel blockers (diltiazem, nicardipine, verapamil)
• Azole antifungals (fluconazole, itraconazole, ketoconazole, voriconazole)
• Macrolide antibiotics (azithromycin, clarithromycin, erythromycin)
• HIV protease inhibitors

Drugs that decrease cyclosporine levels (requiring dose increase) 2:

• Anticonvulsants (carbamazepine, phenytoin, phenobarbital)
• Rifampin
• St. John's wort
• Terbinafine

Statins combined with cyclosporine markedly increase rhabdomyolysis risk; pravastatin is preferred if statin therapy is necessary. 2

Infection Risk

Cyclosporine increases susceptibility to opportunistic infections; screen for tuberculosis, hepatitis B/C, and Strongyloides in appropriate populations. 2, 6

• Consider Pneumocystis jirovecii pneumonia (PJP) prophylaxis when combining cyclosporine with high-dose corticosteroids (>30 mg prednisone equivalent) 6
• Advise patients to seek early medical attention for febrile illness 2
• Vaccination may be less effective during treatment; avoid live attenuated vaccines 1

Special Populations

In HIV-infected patients, confer with the HIV specialist team before initiating cyclosporine due to immunosuppression concerns. 2

Hepatitis B or C should generally be treated before starting cyclosporine, though successful treatment has been reported in hepatitis C patients. 2

---

Treatment Strategy Optimization

Use cyclosporine for acute disease control, bridging to other therapies, or in rotational schemes rather than indefinite continuous therapy. 2, 7

• Maintain concurrent topical therapy to reduce required cyclosporine dose and sustain remission during tapering 2
• Intermittent short courses (up to 16 weeks) reduce toxicity compared to continuous treatment 2
• For psoriasis, 51% of patients achieve ≥75% improvement by 8 weeks, and 79% by 16 weeks 1
• Recurrence of disease activity typically occurs within 4 weeks of stopping cyclosporine 1